Trials / Conditions / Non-muscle Invasive Bladder Cancer (NMIBC)

Non-muscle Invasive Bladder Cancer (NMIBC)

20 registered clinical trials studyying Non-muscle Invasive Bladder Cancer (NMIBC) — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Tumor Budding and T1 Substaging in Urothelial Bladder Cancer NCT07529639	Assiut University	—
Recruiting	Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263	Michael A. O'Donnell	Phase 2
Recruiting	Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study NCT07339761	University of Aarhus	N/A
Recruiting	Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 NCT07225127	University of Washington	—
Not Yet Recruiting	Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladde NCT06829823	ImmunityBio, Inc.	Phase 2
Recruiting	Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High NCT06696794	Shaogang Wang	Phase 3
Recruiting	Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer NCT07187063	Lahey Clinic	N/A
Recruiting	A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer NCT07122414	Suzhou Forlong Biotechnology Co., Ltd	Phase 1 / Phase 2
Recruiting	A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmett NCT06351904	Ractigen Therapeutics.	Phase 1
Recruiting	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone o NCT06186414	Jiangsu Simcere Pharmaceutical Co., Ltd.	Phase 1
Unknown	Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test NCT05176145	Vitadx	N/A
Terminated	Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC. NCT06069453	Fidia Farmaceutici s.p.a.	N/A
Active Not Recruiting	Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer Th NCT04179162	Memorial Sloan Kettering Cancer Center	Phase 1 / Phase 2
Withdrawn	Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors NCT03839472	Case Comprehensive Cancer Center	N/A
Terminated	Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC NCT03719300	Anchiano Therapeutics Israel Ltd.	Phase 2
Completed	Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of NCT03672240	Asieris Pharmaceutical Technologies Co., Ltd.	Phase 1 / Phase 2
Terminated	Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) NCT03167151	University of Oxford	Phase 1 / Phase 2
Unknown	Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident NCT03148158	Mansoura University	—
Unknown	Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side E NCT03038321	Mansoura University	Phase 4
Completed	Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer NCT02009332	Aadi Bioscience, Inc.	Phase 1 / Phase 2